CBAY
Price:
$32.48
Market Cap:
$3.73B
CymaBay Therapeutics, Inc. is a biopharmaceutical company in the clinical development phase, focused on discovering and delivering treatments for liver disorders and various other long-term illnesses. A key experimental therapy in their portfolio is seladelpar (MBX-8025), a selective activator of the peroxisome proliferator activated receptor delta. This compound is currently undergoing a pivotal Phase III clinical trial for primary biliary cholangitis (PBC), and has also concluded a Phase 2b study investigating its use for nonalcoholic steatohepatitis (NASH). Additionally, the company is advancing MBX-2982 through Phase 2a clinical trials, aiming to address hypoglycemia in individuals with ...[Read more]
Industry
Biotechnology
IPO Date
2014-02-03
Stock Exchange
NASDAQ
Ticker
CBAY
According to CymaBay Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -32.81. This represents a change of -65.44% compared to the average of -94.94 of the last 4 quarters.
The mean historical PE Ratio of CymaBay Therapeutics, Inc. over the last ten years is -6.56. The current -32.81 PE Ratio has changed 49.88% with respect to the historical average. Over the past ten years (40 quarters), CBAY's PE Ratio was at its highest in in the December 2019 quarter at -1.15. The PE Ratio was at its lowest in in the June 2023 quarter at -346.09.
Average
-6.56
Median
-4.17
Minimum
-23.81
Maximum
-1.29
Discovering the peaks and valleys of CymaBay Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 667.40%
Maximum Annual PE Ratio = -1.29
Minimum Annual Increase = -79.51%
Minimum Annual PE Ratio = -23.81
| Year | PE Ratio | Change |
|---|---|---|
| 2023 | -23.81 | 414.13% |
| 2022 | -4.63 | 78.50% |
| 2021 | -2.59 | -68.08% |
| 2020 | -8.13 | 532.31% |
| 2019 | -1.29 | -79.51% |
| 2018 | -6.27 | -46.15% |
| 2017 | -11.65 | 667.40% |
| 2016 | -1.52 | -26.22% |
| 2015 | -2.06 | -44.55% |
| 2014 | -3.71 | -70.48% |
The current PE Ratio of CymaBay Therapeutics, Inc. (CBAY) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
-10.34
5-year avg
-8.09
10-year avg
-6.56
CymaBay Therapeutics, Inc.’s PE Ratio is greater than RayzeBio, Inc. Common Stock (-35.73), less than SpringWorks Therapeutics, Inc. (-21.93), less than Mirati Therapeutics, Inc. (-4.46), less than Opthea Limited (-6.40), less than Morphic Holding, Inc. (-15.88), less than MorphoSys AG (-11.81), less than Chinook Therapeutics, Inc. (-14.08), greater than Alpine Immune Sciences, Inc. (-100.94), less than Myovant Sciences Ltd. (-12.18), less than Longboard Pharmaceuticals, Inc. (-25.05),
| Company | PE Ratio | Market cap |
|---|---|---|
| -35.73 | $3.75B | |
| -21.93 | $3.54B | |
| -4.46 | $4.12B | |
| -6.40 | $4.24B | |
| -15.88 | $2.86B | |
| -11.81 | $2.86B | |
| -14.08 | $2.71B | |
| -100.94 | $4.46B | |
| -12.18 | $2.62B | |
| -25.05 | $2.34B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like CymaBay Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like CymaBay Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is CymaBay Therapeutics, Inc.'s PE Ratio?
How is the PE Ratio calculated for CymaBay Therapeutics, Inc. (CBAY)?
What is the highest PE Ratio for CymaBay Therapeutics, Inc. (CBAY)?
What is the 3-year average PE Ratio for CymaBay Therapeutics, Inc. (CBAY)?
What is the 5-year average PE Ratio for CymaBay Therapeutics, Inc. (CBAY)?
How does the current PE Ratio for CymaBay Therapeutics, Inc. (CBAY) compare to its historical average?